Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity
EntityUAM. Departamento de Medicina
10.3390/biomedicines10030727Biomedicines 10.3 (2022): 727
Funded byThis research has been funded by grants from: Asociación Española de Gastroenterología (AEG), Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU), Instituto de Salud Carlos III (FIS12/02557 and PI13/00041) and Universidad de Alcalá (32/2013, 22/2014, 26/2015) and B2017/BMD-3804 MITIC-CM (Comunidad de Madrid) and Halekulani S.L
ProjectGobierno de España. FIS12/02557; Gobierno de España. PIE-13-00041; Comunidad de Madrid. B2017/BMD-3804 MITIC-CM;
SubjectsAIF-1; Anti-TNFs; Crohn’s disease; CRP; Medicina
Rights© 2022 by the authors
Esta obra está bajo una Licencia Creative Commons Atribución 4.0 Internacional.
Background: Recently, increased tissue levels of AIF-1 have been shown in experimental colitis, supporting its role in intestinal inflammation. Therefore, we studied the levels of AIF-1 in Crohn’s disease (CD). Methods: This study included 33 patients with CD (14 men and 19 women) who participated in the PREDICROHN project, a prospective multicenter study of the Spanish Group of Inflammatory bowel disease (GETECCU). Results: This article demonstrates declines with respect to baseline levels of serum AIF-1 in Crohn’s disease (CD) patients after 14 weeks of treatment with anti-TNFs. Furthermore, in patients with active CD (HB ≥ 5), serum AIF-1 levels were significantly higher than those in patients without activity (HB ≤ 4). The study of serum AIF-1 in the same cohort, revealed an area under the ROC curve (AUC) value of AUC = 0.66 (p = 0.014), while for the CRP (C-reactive protein), (AUC) value of 0.69 (p = 0.0066), indicating a similar ability to classify CD patients by their severity. However, the combination of data on serum levels of AIF-1 and CRP improves the predictive ability of these analyses for classifying CD patients as active (HB ≥ 5) or inactive (HB ≤ 4). When we used the odds ratio (OR) formula, we observed that patients with CRP > 5 mg/L or AIF-1 > 200 pg/mL or both conditions were 13 times more likely to show HB ≥ 5 (active CD) than were those with both markers below these thresholds. Conclusion: The development of an algorithm that includes serum levels of AIF-1 and CRP could be useful for assessing Crohn’s disease severity
Files in this item
Google Scholar:Guijarro, Luis G. - Chaparro Sánchez, María - Vera Mendoza, María Isabel - Martín Arranz, María Dolores - Pérez Gisbert, Francisco Javier
This item appears in the following Collection(s)
Showing items related by title, author, creator and subject.
Relationship between IGF-1 and body weight in inflammatory bowel diseases: Cellular and molecular mechanisms involved
Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents Guasch, Montserrat; Cañete, Fiorella; Ordás, Ingrid; Iglesisas-Flores, Eva; Clos, Ariadna; Gisbert, Javier P.; Taxonera, Carlos; Vera Mendoza, María Isabel; Mínguez, Miguel; Guardiola, Jordi; Rivero, Montserrat; Nos, Pilar; Gomollón, Fernando; Barrio, Jesús; Francisco, Ruth de; López-Sanromán, Antonio; Martín Arranz, María Dolores; García Planella, Esther; Camargo, Raquel; García-López, Santiago; Castro, Luisa de; Calvet, Xavier; Esteve, María; Mañosa, Miriam; Doménech, Eugeni
The safety of drugs for inflammatory bowel disease during pregnancy and breastfeeding: the DUMBO registry study protocol of GETECCU